Cypress Capital Management Wy Cut Its Gilead Sciences (GILD) Stake, Truett-hurst (THST) Has 0.4 Sentiment

June 21, 2017 - By Adrian Erickson

Truett-Hurst, Inc. is a holding company. The company has market cap of $9.34 million. The Firm produces and sells wines and other select beverage alcohol products made from wine. It currently has negative earnings. The Company’s divisions include wholesale and direct to consumer.

Cypress Capital Management Llc Wy decreased Gilead Sciences Inc (GILD) stake by 30.11% reported in 2016Q4 SEC filing. Cypress Capital Management Llc Wy sold 9,645 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Cypress Capital Management Llc Wy holds 22,387 shares with $1.64 million value, down from 32,032 last quarter. Gilead Sciences Inc now has $86.64B valuation. The stock increased 1.19% or $0.77 during the last trading session, reaching $65.59. About 30 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 21, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Bard Associates Inc holds 0.38% of its portfolio in Truett-Hurst Inc for 457,844 shares. North Star Investment Management Corp. owns 1.03 million shares or 0.28% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 708 shares. The New York-based Goldman Sachs Group Inc has invested 0% in the stock. Manufacturers Life Insurance Company The, a Ontario – Canada-based fund reported 1,254 shares.

The stock increased 2.93% or $0.06 on June 20, reaching $2.11. About shares traded. Truett-Hurst Inc (THST) has risen 30.77% since June 21, 2016 and is uptrending. It has outperformed by 14.07% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $143,431 activity.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $2.13 earnings per share, down 29.70% or $0.90 from last year’s $3.03 per share. GILD’s profit will be $2.81 billion for 7.70 P/E if the $2.13 EPS becomes a reality. After $2.20 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth.

Since January 3, 2017, it had 0 buys, and 11 sales for $33.68 million activity. $4.93 million worth of stock was sold by MARTIN JOHN C on Monday, April 3. $668,667 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Cogan John Francis. Shares for $337,392 were sold by Alton Gregg H. $1.41M worth of stock was sold by WILSON GAYLE E on Thursday, February 23.